ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA®) for Pancreatic Cancer

  • Post author:
  • Post category:Newsroom

ERYTECH Pharma today announced the final patient has been enrolled in its Phase 2 trial of eryaspase, also known as ERY-ASP or GRASPA®, for the treatment of pancreatic cancer.

Menu